



Medicine Supply Notification

MSN/2024/074

Flixotide[®] (fluticasone) 125micrograms/dose and 250micrograms/dose Evohaler[®]

Tier 2 – medium impact*

Date of issue: 19/06/2024

Link: [Medicines Supply Tool](#)

Summary

- Flixotide[®] (fluticasone) 125micrograms/dose and 250micrograms/dose Evohaler[®] is out of stock from late June until mid-July 2024.
- Flixotide[®] (fluticasone) Accuhaler[®] 100microgram, 250microgram and 500microgram remain available and can support a full uplift in demand.
- Where these are not suitable options, alternative corticosteroid inhalers, including beclomethasone metered dose inhalers, are available.

Actions Required

Where patients have insufficient supplies to last until the re-supply date, clinicians should:

- review and discuss treatment options with them taking into account individual clinical requirements e.g., need for a spacer, to aid selection of an alternative treatment option (see Supporting information);
- consider prescribing sufficient supply of an appropriate strength Flixotide[®] Accuhaler[®], a dry powder inhaler (DPI), to last until the resupply date, in patients able to use this device;
- where patients are already prescribed a Flixotide[®] 125 micrograms/dose Evohaler[®] and a salmeterol 25micrograms inhaler separately, consider prescribing Seretide[®] 125 Evohaler[®] as this combination inhaler delivers the same doses of these components;
- where patients are already prescribed a Flixotide[®] 250 micrograms/dose Evohaler[®] and a salmeterol inhaler separately, consider prescribing Seretide[®] 250 Evohaler[®] as this combination inhaler delivers the same doses of these components;;
- if the above options are not appropriate, consider prescribing an alternative inhaled corticosteroid in line with NICE asthma guidelines (see Supporting information); and
- counsel patients and carers on inhaler technique and dose to administer after switching treatment, and monitor symptom control (see Supporting information).

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Switching from pressurised metered dose inhaler to dry powder inhaler (DPI)

As DPIs are not compatible with spacer devices, they would not be a suitable option for patients who require a spacer. For patients considered suitable for a Flixotide[®] (100microgram, 250microgram or 500microgram) Accuhaler[®], additional counselling will be required regarding the new device and different method of administration and/or dosing regimen prescribed.

Children who are prescribed an alternative fluticasone inhaler should be present during counselling to ensure inhaler technique is correct.

Further guidance including videos advising patients on how to use dry powdered inhalers (Accuhaler[®]) and metered dose inhalers (Evohaler[®]) with spacers can be found on the [Asthma + Lung UK website](#).

Alternative corticosteroid inhaler

NICE have developed tables to support the recommendations on inhaled corticosteroid (ICS) dosages in its guideline on asthma, indicating low, moderate, and high ICS dosages for adult and paediatric maintenance therapy. This can be used as an aid to product selection.

Links to further information

[NICE guideline on asthma](#)

[Inhaled corticosteroid doses for NICE's asthma guideline](#)

[SmPC Flixotide[®] \(fluticasone\) Accuhaler[®]](#)

[SmPC Flixotide[®] \(fluticasone\) Evohaler[®]](#)

[SmPC Seretide[®] Evohaler[®]](#)

[BTS/SIGN guideline on the management of asthma](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.